CA2314494A1 - Anionic polymers as species specific antibacterial agents - Google Patents
Anionic polymers as species specific antibacterial agents Download PDFInfo
- Publication number
- CA2314494A1 CA2314494A1 CA002314494A CA2314494A CA2314494A1 CA 2314494 A1 CA2314494 A1 CA 2314494A1 CA 002314494 A CA002314494 A CA 002314494A CA 2314494 A CA2314494 A CA 2314494A CA 2314494 A1 CA2314494 A1 CA 2314494A1
- Authority
- CA
- Canada
- Prior art keywords
- poly
- polymer
- infection
- acid
- undecenesulfate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/795—Polymers containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Abstract
The present invention relates to the discovery that certain anionic polymers have useful antibacterial activity.
Description
-1 _ _.
ANIONIC POLYMERS AS SPECIES SPECIFIC ANTIBACTERIAL AGENTS
BACKGROUND OF THE INVENTION
The development of antimicrobial chemotherapeutic agents has significantly reduced the morbidity and mortality associated with bacterial infections over the last S century, particularly in developed countries. However, the emergence of drug-resistant bacterial strains threatens the resurgence of diseases long thought to have been conquered. For example, a growing number of cases of drug-resistant tuberculosis have been reported since the mid-1980s, and a recent increase in multiple drug resistant Staphylococcus aureus infections has been observed. As the prevalence of drug-resistant bacteria increases, there is a growing need for new antibacterial agents which are suitable for use against a variety of bacterial targets.
SUMMARY OF THE INVENTION
The present invention relates to the discovery that certain anionic polymers have useful antibacterial activity.
In one embodiment, the invention provides a method of treating a bacterial infection in a patient. The method comprises the step of administering to the patient a therapeutically effective amount of a polymer selected from the group consisting of poly(undecenesulfate), poly(undecenephosphate), poly(undecenesulfonate), poly(styrenesulfonate), poly(undecenoic acid-co-undecenesulfate) and poly(monoalkylmaleic acid).
The invention further relates to pharmaceutical compositions comprising one or more polymers comprising pendant anionic groups in a therapeutically effective amount.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to a method of treating a bacterial infection in a patient, for example, a mammal, such as a human, by administering to the patient a therapeutically effective amount of a polymer selected from poly(undecenesulfate), poly(undecenephosphate), poly(undecenesulfonate), poly(styrenesulfonate), _7_ poly(undecenoic acid-co-undecenesulfate) and poly(monoalkylmaleic acid), copolymers or pharmaceutically acceptable salts thereof.
The polymer can be administered in the acid form, in which 0-100% of the acidic groups are protonated, or in the conjugate base form, wherein 0-100%
the acidic functional groups are deprotonated and carry a negative charge. In the conjugate base form, the negative charge of the polymer is balanced by a suitable number of counter cations, such as alkali metal ions, for example, sodium, potassmm or cesium ions; alkaline earth metal ions, such as magnesium ions or calcium ions; transition metal ions; or substituted or unsubstituted ammonium, (tetraalkylammonium ions, for example). In one embodiment, the cation is a polyvalent metal ion, such as Ca2T, Mg'~, Znz+, A13+, Bi3~, Fez+ or Fe'+
As used herein, a "therapeutically effective amount" is an amount sufficient to inhibit or prevent, partially or totally, a bacteral infection or to reverse the development of a bacterial infection or prevent or reduce its further progression.
1 ~ The polymer to be administered will, preferably, be of a molecular weight which is suitable for the intended mode of administration and allows the polymer to reach and remain (to the extent and duration necessary) within the targeted region of the body. For example, a method for treating an intestinal infection can utilize a polymer of sufficiently high molecular weight to resist absorption, partially or completely, from the gastrointestinal tract into other parts of the body. The polymers can have molecular weights ranging from about 1 to about 1 million Daltons or more, such as about S00 or about 2,000 Daltons to about 500,000 Daltons, about 5,000 Daltons to about 150,000 Daltons or about 25,000 Daltons to about 1 million Daltons.
In a preferred embodiment, the polymer to be administered is selected from the group consisting of poly(undecenesulfate), poly(undecenephosphate), poly(undecene-sulfonate), poly(styrenesulfonate), poly(undecenoic acid-co-undecenesulfate) and poly(monoalkylmaleic acid), where the alkyl group is a linear or branched CZ-C,,-alkyl group. The polymers can include copolymers, such as polymers manufactured by copolymerizing an alkyl-substituted vinyl (e.g., a CZ-C,2 alkyl, such as styrene.
The bacterial infection is, preferably, an infection by a bacterial species selected from the group consisting of Neisseria species, such as Neisseria meningitides and Branhamellcz species, such as Branhamella catarrhalis. The infection can be a systemic infection or a localized infection. Preferably, the infection is localized to one or more of the oral cavity, the eye, the gastrointestinal tract, including the throat and colon, the skin and the ear, such as the ear canal or the middle ear.
In one embodiment, the bacterial infection is an infection by Streptococczzs sanguis and the polymer which is administered is polystyrene sulfonate), poly(undecenesulfate) or poly(undecenesulfonate). The polystyrene sulfonate) is preferably administered in the anionic form in combination with a suitable cation, as described above. For example, the polymer which is administered can be polystyrene sulfonate, Na+) In yet another embodiment, the bacterial infection is an infection by Neisseria meningitides and the polymer to be administered is polystyrene sulfonic acid); polystyrene sulfonate), poly(undecenesulfonate), poly(undecenesulfate), poly(undecenoic acid-co-undecenesulfate) or poly(monoalkylmaleic acid), where the alkyl group is a linear or branched CZ-C,2-alkyl group, preferably a decyl group.
In a further embodiment, the infection is an infection by Branhamella catarhallis (formerly,:hloraxella catarhallis), and the polymer which is administered is poly(styrenesulfonate), poly(styrenesulfonic acid), poly(undecenoic acid), poly(undecenesulfate) and poly(undecenoic acid-co-undecenesulfate).
The quantity of a given polymer to be administered will be determined on an individual basis and will be determined, at least in part, by consideration of the individual's size, the severity of symptoms to be treated and the result sought. The polymer can be administered alone or in a pharmaceutical composition comprising the polymer, one or more acceptable carriers or diluents and, optionally, one or more additional drugs, such as antibiotics, antiinflammatory agents or analgesia.
The polymer can be administered systemically or non-systemically, for example, by subcutaneous or other injection, intravenously, topically, orally, parenterally, transdermally, or rectally. The route of administration selected will generally depend upon whether the infection is systemic or localized. The form in which the polymer will be administered, for example, powder, tablet, capsule, solution, or emulsion, will depend on the route by which it is administered.
The therapeutically effective amount can be administered in a single dose or a series of doses separated by appropriate time intervals, such as hours. Preferably, the -4- _.
polymer is administered non-systemically, for example, orally or topically, for example, by application to the skin, the eye, oral tissue, such as the oral mucosa, or gastrointestinal mucosa.
The polymers of this invention can be administered to the patient by S themselves or in pharmaceutical compositions in which they are mixed with one or more suitable carriers and/or excipients at doses to sufficient to treat the microbial infection. Mixtures of these compounds can also be administered to the patient as a simple mixture or in suitable formulated pharmaceutical compositions.
Techniques for formulation and administration of the compounds of the instant application are known in the art and can be found, for example, in "Remington: the Science and Practice of Pharmacy," 19'h edition, Mack Publishing Co., Easton, PA (1995).
The polymers of use in the present method are preferably substantially non-biodegradable and non-absorbable. That is, the polymers do not substantially break down under physiological conditions into fragments which are absorbable by body tissues. The polymers preferably have a non-hydrolyzable backbone, which is substantially inert under conditions encountered in the target region of the body, such as the gastrointestinal tract.
The polymer can be crosslinked, for example, by the incorporation within the polymer of a multifunctional comonomer. Suitable multifunctional co-monomers include diacrylates, triacrylates and tetraacrylates, dimethacrylates, diacrylamides, diallylacrylamide, di(methacrylamides), and triallylamine. Specific examples include ethylene glycol diacrylate, propylene glycol diacrylate, butylene glycol diacrylate, ethylene glycol dimethacrylate, butylene glycol dimethacrylate, methylene bis(methacrylamide), ethylene bis(acrylamide), ethylene bis(methacrylamide), ethylidene bis(acrylamide), ethylidene bis(methacrylamide), pentaerythritol tetraacrylate, trimethylolpropane triacrylate, bisphenol A
dimethacrylate, and bisphenol A diacrylate. Other suitable multifunctional monomers include polyvinylarenes, such as divinylbenzene.
The polymer can also be cross-linked subsequent to polymerization. For example, a portion of the acid functional groups can be converted to a reactive derivative, as is known in the art. For example, carboxylic acid and sulfonic acid groups react with thionyl chloride to produce, respectively, acyl chloride and sulfonyl chloride groups. These reactive groups can then be reacted with a diamine, a dialcohol or an amino alcohol, preferably diamine, a dialcohol or an amino alcohol in which the amino and/or hydroxyl groups are separated by an alkylene chain, such as a C,-C,g-alkylene chain. This reaction results in the formation of ester and/or amide groups on a given polymer chain which are linked to similar groups on adjacent polymer chains. The extent of cross-linking can be controlled, for example, by controlling the fraction of acid functional groups which are converted to reactive groups.
The amount of crosslinking agent is typically between about 1.0% and about 30% by weight relative to the weight of the polymer, preferably from about 5%
to about 25% by weight.
The polymer or polymers comprising pendant acid functional groups can be administered alone or in combination with one or more additional therapeutic agents, for example, one or more antimicrobial agents, such as those known in the art. For example, the polymer or polymers can be administered in combination with one or more agents, such as antimicrobial agents, which can be employed in the treatment of the particular microbial infection. Suitable antimicrobial agents are known in the art and include isoniazid, rifampin, pyrazinamide, ethambutol, erythromycin, vancomycin, tetracycline, chloramphenicol, ampicillin, cephalosporins, sulfonamides, gentamicin, amoxicillin, penicillin, streptomycin, p-aminosalicyclic acid, clarithromycin, clofazimine, minocycline, ethionamide, cycloserine, kanamycin, amikacin, capreomycin, viomycin, thiacetazone, rifabutin and the quinolones, such as ciprofloxacin, ofloxacin and sparfloxicin.
The term "antimicrobial agent" is intended to include antibacterial agents, antifungal agents, antiseptics and the like. Suitable antimicrobial agents are known in the art and include "Antibacterial agents" include but is not limited to:
naturally occurnng antibiotics produced by microorganisms to suppress the growth of other microorgansims, and agents synthesized or modified in the laboratory which have either bactericidal or bacteriostatic activity, e.g., ~3-lactam antibacterial agents including, e.g. carbencillim; ampicillin, cloxacillin, oxacillin and pieracillin, cephalosporins and other cephems including, e.g. cefaclor, cefamandole, cefazolin, cefoperazone, ceftaxime, cefoxitin, ceftazidime, ceftriazone and carbapenems _6_ including, e.g., imipenem and meropenem; and glycopeptides, macrolides, quinolones (e.g. nalidixic acid), tetracyclines, aminoglycosides (e.g.
Gentamicin and Paromomycin) and further includes antifungal agents. In general if an antibacterial agent is bacteriostatic, it means that the agent essentially stops bacterial cell growth (but does not kill the bacteria); if the agent is bacteriocidal, it means that the agent kills bacterial cells (and may stop growth before killing the bacteria).
If two or more polymers of the invention are administered in combination, they can be administered simultaneously, sequentially or separately, for example, with administration of each compound or two or more groups of compounds separated by a suitable time interval, such as hours. When the polymer or polymers of the invention are administered in combination with one or more additional agents, such as are discussed above, the compound or compounds of the invention and the additional agent or agents can be administered simultaneously, sequentially or separately, for example, with administration of each agent or two or more groups of agents separated by a suitable time interval, such as hours.
The invention will now be further and specifically described by the following examples.
EXAMPLES
Example 1 - Preparation of sulfonated polystyrene gels Polystyrene gels were prepared by polymerizing styrene with divinyl benzene in toluene using about 1 mole% AIBN as initiator as follows:
Polystyrene gel (6% DVB). Styrene (282 mmole, 3.23 mL) was added to a 40 mL vial fitted with a septum cap. Toluene (5 mL) was added and the solution was degassed for 15 min. A solution of AIBN (0.9852 g in 10 mL of toluene) was prepared and 0.5 mL was added to the solution. The solution was further degassed for S min and then maintained at 60°C for 21 hr. The resulting clear colorless gel was washed 5 times with ethanol in a SO mL centrifuge tube and dried overnight in a 70°C forced air oven.
Polystyrene gels were also prepared using this procedure with the following cross-linking levels: 4% DVB; 2% DVB; 1.5% DVB; 1% DVB; and 0.5% DVB.
_'J-Sulfonation of polystyrene gel Dried polystyrene gel was transferred to a 40 mL glass vial. Concentrated sulfuric acid ( 10 mL) was added and the mixture was heated at 100°C
for 1 hr. The resulting brown, swollen gel was allowed to cool to room temperature and was washed exhaustively with methanol until the pH was 4-5. The gel was dried overnight in a 70°C forced air oven. The dried gel was then ground in a coffee grinder, transferred to a 50 mL centrifuge tube, and washed several times with water.
Example 2 - Synthesis of poly(styrenesulfonate) calcium salt To a 500 mL 3-necked round bottomed flask were added 2 g of poly(sodium 4- styrene sulfonate) and 100 mL of deionized water. The mixture was stirred for several minutes until a homogeneous solution was obtained. To this polymer solution was added 6.46 mL of a 0.225 M solution of CaCl2. The reaction mixture was allowed to stir at room temperature for 15 hr.
The reaction mixture was purified by membrane centrifugation using molecular weight 3K cut-off filters. The solution was dried at 70°C in a forced air oven for 24 hours, yielding 1.4 g of the polymer as an off white solid.
Example 3 - Preparation of cross-linked styrenesulfonate copolymers with hydrophobic co-monomers Polystyrenesulfonate gel (2% cross-linked) Polystyrenesulfonate (29.4 mmoles, 5.119 g) and divinylbenzene (0.6 mmoles, 85.5 microL) were dissolved in 10 mL ethanol and 10 mL water in a 40 mL
vial fitted with a septum cap. The solution was degassed by bubbling nitrogen through and 1 mole% AIBN was added as a solution. The polymerization solution was further degassed and the placed in a heated reaction block at 60°C
for 18 h. A
clear, colorless gel formed.
Polystyrenesulfonate-co-styrene gel (75 mole%:23 mole%:2% cross-linked) Polystyrenesulfonate (22.5 mmoles, 3.918 g), styrene (6.90 mmoles, 0.7906 mL), and divinylbenzene (0.6 mmoles, 85.5 microL) were dissolved in _g_ mL ethanol and 10 mL water in a 40 mL vial fitted with a septum cap. The solution was degassed by bubbling nitrogen through and 1 mole% AIBN was added as a solution. The polymerization solution was further degassed and the placed in a heated reaction block at 60°C for 18 h. A clear, colorless gel formed.
5 Example 4 - Effect of variation of anionic groups on bacterial activity.
The minimum inhibitory concentration (MIC) assay is performed according to the Performance Standards for Antimicrobial Susceptibility Testing, 1998, vol.
M100-S8, Eighth Informational Supplement, NCCLS, 940 West Valley Road, Suite 1400, Wayne, PA 19087.
10 Polymers to be tested were dissolved in 0.85% saline to a final concentration of either 830 or 1000 ~ug/ml, the pH was adjusted to 7.0 and the solution was filter-sterilized through a 0.22 ~m filter. Two-fold serial dilutions of polymer were prepared in Mueller-Hinton broth with canons aliquotted into 96-well microtiter plates. The plates were then inoculated with 5 x 105 cells/ml of target organism, and incubated i 8-24 hr at 35°C. The optical density (OD) was then read at 590 nm, and microorganism growth was scored (OD >0.1 is considered to be growth; OD <0.1 is considered growth inhibition). The MIC value was defined as the lowest concentration of compound which inhibits growth.
Results The results of the assay are shown below for a variety of acid-functionalized polymers. Poly(undecenesulfate) (sodium salt) was very active against all Neisseria, and Branhamella, but no other pathogens. Two copolymers that contained the undecenesulfate monomer, were also active only against these same pathogens.
If the sulfate group were replaced with a phosphate group, then the polymer was active only against S. sanguis. If the sulfate group were replaced with a sulfonate group, then the polymer was slightly less active against the Neisseria and Streptococcus, but completely inactive against Branhamella. If the sulfate group were replaced with a carboxylate group, then the polymer was inactive against all pathogens tested.
These examples demonstrate some of the specific antibacterial activity that can be attained by varying the anionic group on the polymer.
Not only is the nature of the anionic group important to activity, but the polymer backbone is also crucial. Poly(undecenesulfate) is very active against Neisseria and Branhczmellu. However, dextran sulfate and poly(vinylsulfate) are completely inactive against these pathogens.
S Sulfonated polystyrene) (sodium salt) was active against Neisseria, and Branhamella. Against Branhamella, significant activity is achieved with a Mw of 400,000-500,000; activity decreases with increasing or decreasing Mw.
Table 1 polymer Bacterial species*
poly( 4-styrene sulfonate, >83 >83 >83 >83 9 28 Na=) Mw=123,900 poly(4-styrene sulfonate, >83 >83 >83 >83 83 9 Na+) Mn=321,600 pol(y(styrene sulfonic acid) >83 >83 >83 >83 9 3 High Mw polystyrene sulfonic acid) >83 >83 <83 >83 <0.339 Na+ Mw 70000 15polystyrene sulfonic acid) >83 >83 >83 >83 9 3 Na+ Mw 500000 poly(undecenoic acid, Na+) >83 >83 >83 83 83 28 poly(undecenesulfonate acid, >83 >83 3 9 3 28 Na~),-poly(undecenesulfate, Na+) >83 >83 I ! <0.33<0.31~
poly(undecenephosphate, Na+)**>83 >83 >83 >83 >83 >83 20poly(undecenoic acid-co-undecenesulfate,~83 >83 9 1 1 1 Na.') poly(undecenoic acid-co-undecenesulfate,>83 >83 28 3 3 3 Na') poly(monodecyl malefic acid, >83 >83 9 28 28 28 Nal) poly(styrenesulfonic acid-co-malefic>83 >83 >83 >83 28 >83 acid, Nay) polystyrene sulfonate, Na' >83 >83 28 83 83 83 ) Mw 1800 25polystyrene sulfonate, Na') >83 >83 <83 >83 83 >83 Vlw 8000 poly(styreme sulfonate, Na') >83 >83 <g3 >83 9 28 Mw 220000 polystyrene sulfonate, Na~) >83 >83 <g3 >83 9 9 Mw 400000 polystyrene sulfonate, Na') >83 >83 >83 83 28 28 Mw 780000 polystyrene sulfonate, Na') >83 >83 83 >83 83 28 Mw 1132000 30polystyrene sulfonate, Na') >83 >83 >83 >83 1 83 Mw = 35,000 polyvinylsulfate potassium >83 >83 >83 >83 28 >83 poly(acrylic acid) (Mw=450,000)>83 >83 >83 >83 >83 >83 sodium dodecyl sulfate '~' >83 >83 28 28 28 9 polyvinyl phosphonic acid) >83 >83 >83 >83 >83 >83 , 35poly(methylvinyl ether-co-malefic>83 >83 >83 >83 >83 >83 acid) poly(anetholesulfonic acid, >83 >83 >83 >83 >83 >83 Na' ) poly(acrylic acid-co-malefic >83 >83 >83 >83 >83 >83 acid) Na' poly(acrylic acid-co-malefic >83 >83 >83 >83 >83 >83 acid) Na' *Bacterial species: 1 = E. coli; 2 = E. Faecium; 3 = S. sanguis; 4 = S.
pnezzmoniae; 5 40 = N. meningitides; 6 = Branhamella catarrhalis -l~-While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.
ANIONIC POLYMERS AS SPECIES SPECIFIC ANTIBACTERIAL AGENTS
BACKGROUND OF THE INVENTION
The development of antimicrobial chemotherapeutic agents has significantly reduced the morbidity and mortality associated with bacterial infections over the last S century, particularly in developed countries. However, the emergence of drug-resistant bacterial strains threatens the resurgence of diseases long thought to have been conquered. For example, a growing number of cases of drug-resistant tuberculosis have been reported since the mid-1980s, and a recent increase in multiple drug resistant Staphylococcus aureus infections has been observed. As the prevalence of drug-resistant bacteria increases, there is a growing need for new antibacterial agents which are suitable for use against a variety of bacterial targets.
SUMMARY OF THE INVENTION
The present invention relates to the discovery that certain anionic polymers have useful antibacterial activity.
In one embodiment, the invention provides a method of treating a bacterial infection in a patient. The method comprises the step of administering to the patient a therapeutically effective amount of a polymer selected from the group consisting of poly(undecenesulfate), poly(undecenephosphate), poly(undecenesulfonate), poly(styrenesulfonate), poly(undecenoic acid-co-undecenesulfate) and poly(monoalkylmaleic acid).
The invention further relates to pharmaceutical compositions comprising one or more polymers comprising pendant anionic groups in a therapeutically effective amount.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to a method of treating a bacterial infection in a patient, for example, a mammal, such as a human, by administering to the patient a therapeutically effective amount of a polymer selected from poly(undecenesulfate), poly(undecenephosphate), poly(undecenesulfonate), poly(styrenesulfonate), _7_ poly(undecenoic acid-co-undecenesulfate) and poly(monoalkylmaleic acid), copolymers or pharmaceutically acceptable salts thereof.
The polymer can be administered in the acid form, in which 0-100% of the acidic groups are protonated, or in the conjugate base form, wherein 0-100%
the acidic functional groups are deprotonated and carry a negative charge. In the conjugate base form, the negative charge of the polymer is balanced by a suitable number of counter cations, such as alkali metal ions, for example, sodium, potassmm or cesium ions; alkaline earth metal ions, such as magnesium ions or calcium ions; transition metal ions; or substituted or unsubstituted ammonium, (tetraalkylammonium ions, for example). In one embodiment, the cation is a polyvalent metal ion, such as Ca2T, Mg'~, Znz+, A13+, Bi3~, Fez+ or Fe'+
As used herein, a "therapeutically effective amount" is an amount sufficient to inhibit or prevent, partially or totally, a bacteral infection or to reverse the development of a bacterial infection or prevent or reduce its further progression.
1 ~ The polymer to be administered will, preferably, be of a molecular weight which is suitable for the intended mode of administration and allows the polymer to reach and remain (to the extent and duration necessary) within the targeted region of the body. For example, a method for treating an intestinal infection can utilize a polymer of sufficiently high molecular weight to resist absorption, partially or completely, from the gastrointestinal tract into other parts of the body. The polymers can have molecular weights ranging from about 1 to about 1 million Daltons or more, such as about S00 or about 2,000 Daltons to about 500,000 Daltons, about 5,000 Daltons to about 150,000 Daltons or about 25,000 Daltons to about 1 million Daltons.
In a preferred embodiment, the polymer to be administered is selected from the group consisting of poly(undecenesulfate), poly(undecenephosphate), poly(undecene-sulfonate), poly(styrenesulfonate), poly(undecenoic acid-co-undecenesulfate) and poly(monoalkylmaleic acid), where the alkyl group is a linear or branched CZ-C,,-alkyl group. The polymers can include copolymers, such as polymers manufactured by copolymerizing an alkyl-substituted vinyl (e.g., a CZ-C,2 alkyl, such as styrene.
The bacterial infection is, preferably, an infection by a bacterial species selected from the group consisting of Neisseria species, such as Neisseria meningitides and Branhamellcz species, such as Branhamella catarrhalis. The infection can be a systemic infection or a localized infection. Preferably, the infection is localized to one or more of the oral cavity, the eye, the gastrointestinal tract, including the throat and colon, the skin and the ear, such as the ear canal or the middle ear.
In one embodiment, the bacterial infection is an infection by Streptococczzs sanguis and the polymer which is administered is polystyrene sulfonate), poly(undecenesulfate) or poly(undecenesulfonate). The polystyrene sulfonate) is preferably administered in the anionic form in combination with a suitable cation, as described above. For example, the polymer which is administered can be polystyrene sulfonate, Na+) In yet another embodiment, the bacterial infection is an infection by Neisseria meningitides and the polymer to be administered is polystyrene sulfonic acid); polystyrene sulfonate), poly(undecenesulfonate), poly(undecenesulfate), poly(undecenoic acid-co-undecenesulfate) or poly(monoalkylmaleic acid), where the alkyl group is a linear or branched CZ-C,2-alkyl group, preferably a decyl group.
In a further embodiment, the infection is an infection by Branhamella catarhallis (formerly,:hloraxella catarhallis), and the polymer which is administered is poly(styrenesulfonate), poly(styrenesulfonic acid), poly(undecenoic acid), poly(undecenesulfate) and poly(undecenoic acid-co-undecenesulfate).
The quantity of a given polymer to be administered will be determined on an individual basis and will be determined, at least in part, by consideration of the individual's size, the severity of symptoms to be treated and the result sought. The polymer can be administered alone or in a pharmaceutical composition comprising the polymer, one or more acceptable carriers or diluents and, optionally, one or more additional drugs, such as antibiotics, antiinflammatory agents or analgesia.
The polymer can be administered systemically or non-systemically, for example, by subcutaneous or other injection, intravenously, topically, orally, parenterally, transdermally, or rectally. The route of administration selected will generally depend upon whether the infection is systemic or localized. The form in which the polymer will be administered, for example, powder, tablet, capsule, solution, or emulsion, will depend on the route by which it is administered.
The therapeutically effective amount can be administered in a single dose or a series of doses separated by appropriate time intervals, such as hours. Preferably, the -4- _.
polymer is administered non-systemically, for example, orally or topically, for example, by application to the skin, the eye, oral tissue, such as the oral mucosa, or gastrointestinal mucosa.
The polymers of this invention can be administered to the patient by S themselves or in pharmaceutical compositions in which they are mixed with one or more suitable carriers and/or excipients at doses to sufficient to treat the microbial infection. Mixtures of these compounds can also be administered to the patient as a simple mixture or in suitable formulated pharmaceutical compositions.
Techniques for formulation and administration of the compounds of the instant application are known in the art and can be found, for example, in "Remington: the Science and Practice of Pharmacy," 19'h edition, Mack Publishing Co., Easton, PA (1995).
The polymers of use in the present method are preferably substantially non-biodegradable and non-absorbable. That is, the polymers do not substantially break down under physiological conditions into fragments which are absorbable by body tissues. The polymers preferably have a non-hydrolyzable backbone, which is substantially inert under conditions encountered in the target region of the body, such as the gastrointestinal tract.
The polymer can be crosslinked, for example, by the incorporation within the polymer of a multifunctional comonomer. Suitable multifunctional co-monomers include diacrylates, triacrylates and tetraacrylates, dimethacrylates, diacrylamides, diallylacrylamide, di(methacrylamides), and triallylamine. Specific examples include ethylene glycol diacrylate, propylene glycol diacrylate, butylene glycol diacrylate, ethylene glycol dimethacrylate, butylene glycol dimethacrylate, methylene bis(methacrylamide), ethylene bis(acrylamide), ethylene bis(methacrylamide), ethylidene bis(acrylamide), ethylidene bis(methacrylamide), pentaerythritol tetraacrylate, trimethylolpropane triacrylate, bisphenol A
dimethacrylate, and bisphenol A diacrylate. Other suitable multifunctional monomers include polyvinylarenes, such as divinylbenzene.
The polymer can also be cross-linked subsequent to polymerization. For example, a portion of the acid functional groups can be converted to a reactive derivative, as is known in the art. For example, carboxylic acid and sulfonic acid groups react with thionyl chloride to produce, respectively, acyl chloride and sulfonyl chloride groups. These reactive groups can then be reacted with a diamine, a dialcohol or an amino alcohol, preferably diamine, a dialcohol or an amino alcohol in which the amino and/or hydroxyl groups are separated by an alkylene chain, such as a C,-C,g-alkylene chain. This reaction results in the formation of ester and/or amide groups on a given polymer chain which are linked to similar groups on adjacent polymer chains. The extent of cross-linking can be controlled, for example, by controlling the fraction of acid functional groups which are converted to reactive groups.
The amount of crosslinking agent is typically between about 1.0% and about 30% by weight relative to the weight of the polymer, preferably from about 5%
to about 25% by weight.
The polymer or polymers comprising pendant acid functional groups can be administered alone or in combination with one or more additional therapeutic agents, for example, one or more antimicrobial agents, such as those known in the art. For example, the polymer or polymers can be administered in combination with one or more agents, such as antimicrobial agents, which can be employed in the treatment of the particular microbial infection. Suitable antimicrobial agents are known in the art and include isoniazid, rifampin, pyrazinamide, ethambutol, erythromycin, vancomycin, tetracycline, chloramphenicol, ampicillin, cephalosporins, sulfonamides, gentamicin, amoxicillin, penicillin, streptomycin, p-aminosalicyclic acid, clarithromycin, clofazimine, minocycline, ethionamide, cycloserine, kanamycin, amikacin, capreomycin, viomycin, thiacetazone, rifabutin and the quinolones, such as ciprofloxacin, ofloxacin and sparfloxicin.
The term "antimicrobial agent" is intended to include antibacterial agents, antifungal agents, antiseptics and the like. Suitable antimicrobial agents are known in the art and include "Antibacterial agents" include but is not limited to:
naturally occurnng antibiotics produced by microorganisms to suppress the growth of other microorgansims, and agents synthesized or modified in the laboratory which have either bactericidal or bacteriostatic activity, e.g., ~3-lactam antibacterial agents including, e.g. carbencillim; ampicillin, cloxacillin, oxacillin and pieracillin, cephalosporins and other cephems including, e.g. cefaclor, cefamandole, cefazolin, cefoperazone, ceftaxime, cefoxitin, ceftazidime, ceftriazone and carbapenems _6_ including, e.g., imipenem and meropenem; and glycopeptides, macrolides, quinolones (e.g. nalidixic acid), tetracyclines, aminoglycosides (e.g.
Gentamicin and Paromomycin) and further includes antifungal agents. In general if an antibacterial agent is bacteriostatic, it means that the agent essentially stops bacterial cell growth (but does not kill the bacteria); if the agent is bacteriocidal, it means that the agent kills bacterial cells (and may stop growth before killing the bacteria).
If two or more polymers of the invention are administered in combination, they can be administered simultaneously, sequentially or separately, for example, with administration of each compound or two or more groups of compounds separated by a suitable time interval, such as hours. When the polymer or polymers of the invention are administered in combination with one or more additional agents, such as are discussed above, the compound or compounds of the invention and the additional agent or agents can be administered simultaneously, sequentially or separately, for example, with administration of each agent or two or more groups of agents separated by a suitable time interval, such as hours.
The invention will now be further and specifically described by the following examples.
EXAMPLES
Example 1 - Preparation of sulfonated polystyrene gels Polystyrene gels were prepared by polymerizing styrene with divinyl benzene in toluene using about 1 mole% AIBN as initiator as follows:
Polystyrene gel (6% DVB). Styrene (282 mmole, 3.23 mL) was added to a 40 mL vial fitted with a septum cap. Toluene (5 mL) was added and the solution was degassed for 15 min. A solution of AIBN (0.9852 g in 10 mL of toluene) was prepared and 0.5 mL was added to the solution. The solution was further degassed for S min and then maintained at 60°C for 21 hr. The resulting clear colorless gel was washed 5 times with ethanol in a SO mL centrifuge tube and dried overnight in a 70°C forced air oven.
Polystyrene gels were also prepared using this procedure with the following cross-linking levels: 4% DVB; 2% DVB; 1.5% DVB; 1% DVB; and 0.5% DVB.
_'J-Sulfonation of polystyrene gel Dried polystyrene gel was transferred to a 40 mL glass vial. Concentrated sulfuric acid ( 10 mL) was added and the mixture was heated at 100°C
for 1 hr. The resulting brown, swollen gel was allowed to cool to room temperature and was washed exhaustively with methanol until the pH was 4-5. The gel was dried overnight in a 70°C forced air oven. The dried gel was then ground in a coffee grinder, transferred to a 50 mL centrifuge tube, and washed several times with water.
Example 2 - Synthesis of poly(styrenesulfonate) calcium salt To a 500 mL 3-necked round bottomed flask were added 2 g of poly(sodium 4- styrene sulfonate) and 100 mL of deionized water. The mixture was stirred for several minutes until a homogeneous solution was obtained. To this polymer solution was added 6.46 mL of a 0.225 M solution of CaCl2. The reaction mixture was allowed to stir at room temperature for 15 hr.
The reaction mixture was purified by membrane centrifugation using molecular weight 3K cut-off filters. The solution was dried at 70°C in a forced air oven for 24 hours, yielding 1.4 g of the polymer as an off white solid.
Example 3 - Preparation of cross-linked styrenesulfonate copolymers with hydrophobic co-monomers Polystyrenesulfonate gel (2% cross-linked) Polystyrenesulfonate (29.4 mmoles, 5.119 g) and divinylbenzene (0.6 mmoles, 85.5 microL) were dissolved in 10 mL ethanol and 10 mL water in a 40 mL
vial fitted with a septum cap. The solution was degassed by bubbling nitrogen through and 1 mole% AIBN was added as a solution. The polymerization solution was further degassed and the placed in a heated reaction block at 60°C
for 18 h. A
clear, colorless gel formed.
Polystyrenesulfonate-co-styrene gel (75 mole%:23 mole%:2% cross-linked) Polystyrenesulfonate (22.5 mmoles, 3.918 g), styrene (6.90 mmoles, 0.7906 mL), and divinylbenzene (0.6 mmoles, 85.5 microL) were dissolved in _g_ mL ethanol and 10 mL water in a 40 mL vial fitted with a septum cap. The solution was degassed by bubbling nitrogen through and 1 mole% AIBN was added as a solution. The polymerization solution was further degassed and the placed in a heated reaction block at 60°C for 18 h. A clear, colorless gel formed.
5 Example 4 - Effect of variation of anionic groups on bacterial activity.
The minimum inhibitory concentration (MIC) assay is performed according to the Performance Standards for Antimicrobial Susceptibility Testing, 1998, vol.
M100-S8, Eighth Informational Supplement, NCCLS, 940 West Valley Road, Suite 1400, Wayne, PA 19087.
10 Polymers to be tested were dissolved in 0.85% saline to a final concentration of either 830 or 1000 ~ug/ml, the pH was adjusted to 7.0 and the solution was filter-sterilized through a 0.22 ~m filter. Two-fold serial dilutions of polymer were prepared in Mueller-Hinton broth with canons aliquotted into 96-well microtiter plates. The plates were then inoculated with 5 x 105 cells/ml of target organism, and incubated i 8-24 hr at 35°C. The optical density (OD) was then read at 590 nm, and microorganism growth was scored (OD >0.1 is considered to be growth; OD <0.1 is considered growth inhibition). The MIC value was defined as the lowest concentration of compound which inhibits growth.
Results The results of the assay are shown below for a variety of acid-functionalized polymers. Poly(undecenesulfate) (sodium salt) was very active against all Neisseria, and Branhamella, but no other pathogens. Two copolymers that contained the undecenesulfate monomer, were also active only against these same pathogens.
If the sulfate group were replaced with a phosphate group, then the polymer was active only against S. sanguis. If the sulfate group were replaced with a sulfonate group, then the polymer was slightly less active against the Neisseria and Streptococcus, but completely inactive against Branhamella. If the sulfate group were replaced with a carboxylate group, then the polymer was inactive against all pathogens tested.
These examples demonstrate some of the specific antibacterial activity that can be attained by varying the anionic group on the polymer.
Not only is the nature of the anionic group important to activity, but the polymer backbone is also crucial. Poly(undecenesulfate) is very active against Neisseria and Branhczmellu. However, dextran sulfate and poly(vinylsulfate) are completely inactive against these pathogens.
S Sulfonated polystyrene) (sodium salt) was active against Neisseria, and Branhamella. Against Branhamella, significant activity is achieved with a Mw of 400,000-500,000; activity decreases with increasing or decreasing Mw.
Table 1 polymer Bacterial species*
poly( 4-styrene sulfonate, >83 >83 >83 >83 9 28 Na=) Mw=123,900 poly(4-styrene sulfonate, >83 >83 >83 >83 83 9 Na+) Mn=321,600 pol(y(styrene sulfonic acid) >83 >83 >83 >83 9 3 High Mw polystyrene sulfonic acid) >83 >83 <83 >83 <0.339 Na+ Mw 70000 15polystyrene sulfonic acid) >83 >83 >83 >83 9 3 Na+ Mw 500000 poly(undecenoic acid, Na+) >83 >83 >83 83 83 28 poly(undecenesulfonate acid, >83 >83 3 9 3 28 Na~),-poly(undecenesulfate, Na+) >83 >83 I ! <0.33<0.31~
poly(undecenephosphate, Na+)**>83 >83 >83 >83 >83 >83 20poly(undecenoic acid-co-undecenesulfate,~83 >83 9 1 1 1 Na.') poly(undecenoic acid-co-undecenesulfate,>83 >83 28 3 3 3 Na') poly(monodecyl malefic acid, >83 >83 9 28 28 28 Nal) poly(styrenesulfonic acid-co-malefic>83 >83 >83 >83 28 >83 acid, Nay) polystyrene sulfonate, Na' >83 >83 28 83 83 83 ) Mw 1800 25polystyrene sulfonate, Na') >83 >83 <83 >83 83 >83 Vlw 8000 poly(styreme sulfonate, Na') >83 >83 <g3 >83 9 28 Mw 220000 polystyrene sulfonate, Na~) >83 >83 <g3 >83 9 9 Mw 400000 polystyrene sulfonate, Na') >83 >83 >83 83 28 28 Mw 780000 polystyrene sulfonate, Na') >83 >83 83 >83 83 28 Mw 1132000 30polystyrene sulfonate, Na') >83 >83 >83 >83 1 83 Mw = 35,000 polyvinylsulfate potassium >83 >83 >83 >83 28 >83 poly(acrylic acid) (Mw=450,000)>83 >83 >83 >83 >83 >83 sodium dodecyl sulfate '~' >83 >83 28 28 28 9 polyvinyl phosphonic acid) >83 >83 >83 >83 >83 >83 , 35poly(methylvinyl ether-co-malefic>83 >83 >83 >83 >83 >83 acid) poly(anetholesulfonic acid, >83 >83 >83 >83 >83 >83 Na' ) poly(acrylic acid-co-malefic >83 >83 >83 >83 >83 >83 acid) Na' poly(acrylic acid-co-malefic >83 >83 >83 >83 >83 >83 acid) Na' *Bacterial species: 1 = E. coli; 2 = E. Faecium; 3 = S. sanguis; 4 = S.
pnezzmoniae; 5 40 = N. meningitides; 6 = Branhamella catarrhalis -l~-While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.
Claims (12)
1. A method of treating a bacterial infection in a patient, comprising administering to the patient a therapeutically effective amount of a polymer selected from the group consisting of poly(undecenesulfate), poly(undecenephosphate), poly(undecenesulfonate), poly(styrenesulfonate), poly(undecenoic acid-co-undecenesulfate) and poly(mono-C2-C12-alkylmaleic acid).
2. The method of Claim 1 wherein the bacterial infection is an infection by a bacterial species selected from the group consisting of Neisseria species and Morarella species.
3. The method of Claim 2 wherein the bacterial infection is an infection by Neisseria meraingitidis or Moraxella catarrhalis.
4. The method of Claim 3 wherein the bacterial infection is an infection by Streptococcus sanguis and the polymer which is administered is polystyrene sulfonate), poly(undecenesulfate) or poly(undecenesulfonate).
5. The method of Claim 4 wherein the polymer is poly(styrene sulfonate, Na+).
6. The method of Claim 5 wherein the polymer has a molecular weight less than about 700,000 daltons.
7. The method of Claim 6 wherein the polymer has a molecular weight less than about 500,000 daltons.
8. The method of Claim 7 wherein the polymer has a molecular weight less than about 400,000 daltons.
9. The method of Claim 1 wherein the bacterial infection is an infection by Streptococcus pneumoniae and the polymer which is administered is poly(undecenesulfonate), poly(undecenesulfate) or poly(undecenoic acid-co-undecenesulfate).
10. The method of Claim 1 wherein the bacterial infection is an infection by Neisseria meningitidis and the polymer polystyrene sulfonic acid);
polystyrene sulfonate), poly(undecenesulfonate), poly(undecenesulfate), poly(undecenoic acid-co-undecenesulfate) or poly(C2-C12-alkylmaleic acid).
polystyrene sulfonate), poly(undecenesulfonate), poly(undecenesulfate), poly(undecenoic acid-co-undecenesulfate) or poly(C2-C12-alkylmaleic acid).
11. The method of Claim 10 wherein the polymer is poly(monodecylmaleic acid).
12. The method of Claim 1 wherein the infection is an infection by Moraxella catarhalis, and the polymer which is administered is poly(styrenesulfonate), poly(styrenesulfonic acid), poly(undecenoic acid) and poly(undecenesulfate), poly(undecenoic acid-co-undecenesulfate).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20151700P | 2000-05-02 | 2000-05-02 | |
| US60/201,517 | 2000-05-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2314494A1 true CA2314494A1 (en) | 2001-11-02 |
Family
ID=22746150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002314494A Abandoned CA2314494A1 (en) | 2000-05-02 | 2000-07-20 | Anionic polymers as species specific antibacterial agents |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US6730295B2 (en) |
| CA (1) | CA2314494A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6290946B1 (en) * | 1999-05-13 | 2001-09-18 | Geltex Pharmaceuticals, Inc. | Anionic polymers as toxin binders and antibacterial agents |
| CN100411625C (en) * | 2002-07-22 | 2008-08-20 | 基酶有限公司 | Poly(potassium and sodium styrene sulfonate), its manufacture and its uses |
| US8795730B2 (en) * | 2006-01-31 | 2014-08-05 | David John Vachon | Compositions and methods for promoting the healing of tissue of multicellular organisms |
| WO2007089902A2 (en) * | 2006-01-31 | 2007-08-09 | David Vachon | Compositions and methods for promoting the healing of tissue of multicellular organisms |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3224941A (en) | 1963-01-21 | 1965-12-21 | Lilly Co Eli | Resin compositions and method for controlling diarrhea |
| US3466365A (en) | 1967-07-24 | 1969-09-09 | White Lab Inc | Antiviral compositions and method of use |
| GB1466702A (en) | 1973-02-09 | 1977-03-09 | Sandoz Ltd | Polymer encapsulated-activated carbon |
| US3987163A (en) | 1973-07-27 | 1976-10-19 | Burton, Parsons And Company, Inc. | Polystyrene sulfonate containing opthalmic solutions |
| IE44690B1 (en) | 1976-02-04 | 1982-02-24 | Rohm & Haas | Pharmaceutical compositions containing polyvinylbenzenosulfonic acids |
| US4395392A (en) | 1980-06-24 | 1983-07-26 | Adria Laboratories Inc. | Method for treating kidney stones |
| US4362711A (en) | 1980-07-11 | 1982-12-07 | Evreka Inc. | Blood cholesterol level reducing agent and method |
| US5171738A (en) | 1982-10-04 | 1992-12-15 | Toray Industries, Inc. | Method of treating malignant tumors |
| US5435821A (en) | 1985-12-12 | 1995-07-25 | Exxon Research & Engineering Co. | Controlled release vegetation enhancement agents coated with sulfonated polymers, method of production and prcesses of use |
| US5071759A (en) | 1986-05-30 | 1991-12-10 | The United States Of America As Represented By The Secretary Of The Army | Hybridoma cell lines and monoclonal antibodies to clostridum difficile toxins A and B |
| US5091171B2 (en) | 1986-12-23 | 1997-07-15 | Tristrata Inc | Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use |
| JPS6422551A (en) | 1987-07-16 | 1989-01-25 | Dainippon Ink & Chemicals | Composite film for lid |
| IL90388A (en) | 1988-05-26 | 1993-08-18 | Duphar Int Res | Pharmaceutical compositions having anti- endotoxic activity containing a novel active fraction from lactulose syrup, and a method for its preparation |
| US5149523A (en) | 1989-06-20 | 1992-09-22 | Aktiebolaget Hassle | Polystyrenesulfonate-drug complex and solid dosage forms thereof |
| US5093130A (en) | 1989-09-26 | 1992-03-03 | Plant Genetics | Powder coated hydrogel capsules |
| US5736139A (en) | 1989-10-31 | 1998-04-07 | Ochidian Pharmaceuticals, Inc. | Treatment of Clostridium difficile induced disease |
| US5601823A (en) | 1989-10-31 | 1997-02-11 | Ophidian Pharmaceuticals, Inc. | Avian antitoxins to clostridium difficle toxin A |
| US5231003A (en) | 1990-05-11 | 1993-07-27 | Cambridge Bioscience Corporation | Monoclonal antibodies specific for toxin b of clostridium difficile |
| US5149543A (en) | 1990-10-05 | 1992-09-22 | Massachusetts Institute Of Technology | Ionically cross-linked polymeric microcapsules |
| FR2669535A1 (en) | 1990-11-26 | 1992-05-29 | Medgenix Group Sa | Use of polysulphonated macromolecules as a medicament |
| AU2672892A (en) | 1991-09-17 | 1993-04-27 | Alcon Laboratories, Inc. | Compositions containing quinolone antibiotics and sulfonate of polystyrol |
| US5424063A (en) | 1992-01-09 | 1995-06-13 | The Dow Chemical Company | Narrow poly- and mono-dispersed anionic oligomers, and their uses, formulations and process |
| US5277820A (en) | 1992-02-06 | 1994-01-11 | Hemocleanse, Inc. | Device and method for extracorporeal blood treatment |
| US5474765A (en) | 1992-03-23 | 1995-12-12 | Ut Sw Medical Ctr At Dallas | Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells |
| US5324718A (en) | 1992-07-14 | 1994-06-28 | Thorsteinn Loftsson | Cyclodextrin/drug complexation |
| US5643562A (en) | 1993-03-29 | 1997-07-01 | Queen's University Of Kingston | Method for treating amyloidosis |
| US5614559A (en) | 1993-11-23 | 1997-03-25 | Procept Inc. | Compound for inhibiting HIV infectivity |
| US5484773A (en) | 1994-02-14 | 1996-01-16 | Alberta Research Council | Treatment of antibiotic associated diarrhea |
| AU690656B2 (en) | 1994-03-11 | 1998-04-30 | Pharmacopeia Drug Discovery, Inc. | Sulfonamide derivatives and their use |
| AU702405B2 (en) | 1994-09-06 | 1999-02-18 | Immucell Corporation | Therapeutic treatment of clostridium difficile associated diseases |
| EP0800862B1 (en) | 1994-12-26 | 2002-02-27 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Adsorbent for endotoxin, tumor necrosis factor-alpha or interleukins, method for removal via adsorption, and adsorber |
| US5610023A (en) | 1995-03-31 | 1997-03-11 | Lee Laboratories, Inc. | Method of purification of clostridium difficile toxin A and production of mono-specific antibodies |
| DE19515554C2 (en) | 1995-04-27 | 1999-06-17 | Braun Melsungen Ag | Use of an agent and device for the simultaneous extracorporeal elimination of tumor necrosis factor alpha and bacterial lipopolysaccharides from whole blood and / or blood plasma |
| US5700458A (en) | 1996-09-20 | 1997-12-23 | Geltex Pharmaceuticals Inc. | Acid-functionalized saccharides as polyvalent anti-infectives |
| US5800803A (en) | 1997-02-10 | 1998-09-01 | Colgate-Palmolive Company | Oral composition exhibiting enhanced uptake by dental tissue of noncationic antibacterial agents |
| US6007803A (en) | 1997-09-19 | 1999-12-28 | Geltex Pharmaceuticals, Inc. | Ionic polymers as toxin binding agents |
| US6060235A (en) | 1997-09-19 | 2000-05-09 | Geltex Pharmaceuticals, Inc. | Antiviral polymers comprising acid functional groups and hydrophobic groups |
| WO1999020285A1 (en) | 1997-10-16 | 1999-04-29 | Sanwa Kagaku Kenkyusho Co., Ltd. | Gel preparations containing polystyrenesulfonate |
| US6290946B1 (en) * | 1999-05-13 | 2001-09-18 | Geltex Pharmaceuticals, Inc. | Anionic polymers as toxin binders and antibacterial agents |
| US6270755B1 (en) * | 1999-05-13 | 2001-08-07 | Geltex Pharmaceuticals, Inc. | Anionic polymers as toxin binders |
-
2000
- 2000-07-20 CA CA002314494A patent/CA2314494A1/en not_active Abandoned
-
2001
- 2001-05-01 US US09/847,053 patent/US6730295B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US20020034491A1 (en) | 2002-03-21 |
| US6730295B2 (en) | 2004-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7678369B2 (en) | Anionic polymers as toxin binders and antibacterial agents | |
| KR100742433B1 (en) | Anionic polymers as toxin binders and antibacterial agents | |
| BG97458A (en) | Preparations and methods for the treatment of the alimentary canal | |
| US6730295B2 (en) | Anionic polymers as species specific antibacterial agents | |
| US6011030A (en) | Method of treating symptoms of microbial infection or sepsis | |
| US6482402B1 (en) | Antimicrobial compositions and methods | |
| Slama et al. | Comparative efficacy of prophylactic cephalothin and cefamandole for elective colon surgery: results of a prospective, randomized, double-blind study | |
| KR20050030208A (en) | Poly(potassium and sodium styrene sulfonate), its manufacture and its uses | |
| EP3220923B1 (en) | Copolymer and method for treatment of bacterial infection | |
| JP7116428B2 (en) | Infectious disease drug | |
| EP1800686A2 (en) | Anionic polymers as toxin binders and antibacterial agents | |
| Michael et al. | Hybrid PVA/alginate for extended delivery of antibiotic | |
| AU686829B2 (en) | Pharmaceutical compositions containing triclosan or derivatives thereof and EDTA or EGTA | |
| Xue et al. | Antimicrobial Guanidinylate Polycarbonates Show Oral in Vivo Efficacy Against Clostridioides Difficile | |
| MXPA01011387A (en) | Anionic polymers as toxin binders and antibacterial agents | |
| ZA200109290B (en) | Anionic polymers as toxin binders and antibacterial agents. | |
| CN115040500A (en) | Antibacterial nano-particles, lyotropic liquid crystal precursor solution spray dressing and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |